Omalizumab: An Optimal Choice for Patients with Severe Allergic Asthma

Omalizumab is the first monoclonal antibody that was globally approved as a personalized treatment option for patients with moderate-to-severe allergic asthma. This review summarizes the knowledge of almost two decades of use of omalizumab to answer some important everyday clinical practice question...

Descripción completa

Detalles Bibliográficos
Autores principales: Kotoulas, Serafeim Chrysovalantis, Tsiouprou, Ioanna, Fouka, Eva, Pataka, Athanasia, Papakosta, Despoina, Porpodis, Konstantinos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8878072/
https://www.ncbi.nlm.nih.gov/pubmed/35207654
http://dx.doi.org/10.3390/jpm12020165

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8878072/
https://www.ncbi.nlm.nih.gov/pubmed/35207654
http://dx.doi.org/10.3390/jpm12020165

Ejemplares similares